Pdt Partners, LLC Glaukos Corp Transaction History

Pdt Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$44.33 - $57.82 $1.62 Million - $2.11 Million	-36,451 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$40.27 - $56.99 $1.54 Million - $2.17 Million	-38,158 Reduced 51.14%	36,451 $1.62 Million
Q3 2021 Nov 15, 2021	BUY	$47.43 - $84.23 $1.11 Million - $1.96 Million	23,318 Added 45.46%	74,609 $3.59 Million
Q2 2021 Aug 16, 2021	BUY	$73.06 - $97.7 $245,554 - $328,369	3,361 Added 7.01%	51,291 $4.35 Million
Q1 2021 May 17, 2021	SELL	$70.43 - $97.42 $1.91 Million - $2.65 Million	-27,186 Reduced 36.19%	47,930 $4.02 Million

Q4 2020 Feb 16, 2021	BUY	$48.9 - $75.26 $279,512 - $430,186	5,716 Added 8.24%	75,116 $5.65 Million
Q3 2020 Nov 16, 2020	BUY	$37.23 - $50.97 $2.58 Million - $3.54 Million	69,400 New	69,400 $3.44 Million
Q1 2020 May 15, 2020	SELL	$25.53 - $70.14 $122,671 - $337,022	-4,805 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$54.18 - $65.64 $260,334 - $315,400	4,805 New	4,805 $262,000
Q3 2018 Nov 14, 2018	SELL	$38.13 - $68.37 $2.43 Million - $4.36 Million	-63,800 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$27.62 - $44.51 $1.76 Million - $2.84 Million	63,800 New	63,800 $2.59 Million

273

43.6M

89.8K

236K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $5.63B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.